Research programme: anticancer therapeutics - Global Pharmatech

Drug Profile

Research programme: anticancer therapeutics - Global Pharmatech

Alternative Names: DiAoNing

Latest Information Update: 16 Oct 2007

Price : $50

At a glance

  • Originator Changchun XinYu Pharmaceutical
  • Class Antineoplastics; Herbal medicines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Oct 2007 No development reported - Preclinical for Cancer in China (unspecified route)
  • 30 Jun 2005 Preclinical trials in Cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top